Trial Profile
An efficacy, safety, and pharmacokinetics/pharmacodynamic relationship study of L-dopa/carbidopa [levodopa/carbidopa] in a novel release formulation in parkinson's disease patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Osmotica Pharmaceutical; RVL Pharmaceuticals
- 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2007 New trial record.